The Proposed Ballot Measure Would Decriminalize Psychedelic Plants and Fungi Such as Psilocybin Mushrooms
New Research on Psilocybin From Magic Mushrooms Further Validates Reform Efforts
Decriminalization of psychedelic plants and fungi such as psilocybin mushrooms and ayahuasca moved one step closer to becoming a reality in the nation’s capital following initial approval by the Washington D.C. Board of Elections. The initiative will attempt to reform D.C. laws regarding psychedelics and if successful will move them to the lowest level of priority for local law enforcement.
On Wednesday, the D.C. Board of Elections agreed to allow the measure to move forward. The next step will be for the board to approve a short title and summary statement followed by a meeting designed to allow the public to weigh in on the matter.
If and when those hurdles are cleared, the proposal will move to a 10-day challenge period followed by another board meeting to grand final approval on the initiative’s language. Last but not least, the campaign will need to garner 25,000 signatures in support of the measure within 180 days for it to be officially placed on the November 2020 ballot.
Following Wednesday’s hearing, supporters of the ballot initiative had the opportunity to speak to the Elections Board on the medical benefits of psychedelic plants and mushrooms.
Jesse Gould, military veteran and founder of the Heroic Hearts Project said: “Entheogenic plants saved my life.” Heroic Hearts helps connect veterans to Ayahuasca treatment. Some research has shown that Ayahuasca may help treat addiction, anxiety, treatment-resistant depression, and PTSD.
Gould also wrote a letter to the board dated January 30, 2020, which included the following excerpts:
“I am writing to you today as both a military veteran and as a US citizen and I respectfully request your support of the initiative to Decriminalize entheogenic plants and fungi. As a veteran, I represent the voice of a community that is suffering through an unprecedented mental health crisis. As a civilian, I bring the simple request to reexamine certain laws that are now outdated and preventing the emergence of effective treatment options.”
“Decriminalization can only bring safety and knowledge around the therapeutic use of substances that are already widely available. It will allow therapists to speak candidly to clients, researchers and students to pursue areas of study without fear of retribution, and an overall more educated society.”
Read Gould’s full letter here.
Also providing testimony in support of the movement was Melissa Lavasani, spokesperson for Decriminalize Nature D.C., the group responsible for the Psychedelics reform ballot initiative.
In a January interview with Marijuana Moment, when asked about the possibility of pursuing a legislative approach in addition to the current ballot initiative, Lavasani answered;
“Yes, absolutely. This is definitely a two-pronged tactic here. We are talking to Council about potentially getting a bill through that way, legislatively.”
According to the group’s website, Decriminalize Nature D.C. “is a campaign organized by D.C. residents to change government policy and make entheogenic plants and fungi the lowest law enforcement priority. This is the first step towards ensuring safe, equitable access for all people to entheogenic plants and fungi.”
The different forms of psychedelic plants and fungi the measure refers to includes: “Entheogenic plants, fungi, and natural sources (as defined herein), such as mushrooms, cacti, iboga containing plants and /or extracted combinations of plants similar to Ayahuasca; and limited to those containing the following types of compounds: indole amines, tryptamines, phenethylamines.”
The campaign’s website includes a detailed list of specific examples of different types of entheogenic plants, fungi and cacti which include:
- Fungi/mushrooms containing Psilocybin.
- Cacti containing Peyote.
- Plants used to create Ayahuasca and DMT.
- Read the full list here.
If you’d like to support Decriminalize Nature D.C. in their quest to decriminalize psychedelic plants and fungi in the nation’s capital you can donate to the cause here.
New Psilocybin Research Helps Validate Reform Efforts
Further evidence in support of the psychedelics reform movement was uncovered recently after a new study found that a single dose of psilocybin from magic mushrooms provided long-term relief to cancer patients suffering from anxiety and depression.
After receiving a dose of psilocybin combined with psychotherapy, patients reported a reduction in anxiety, depression, hopelessness, demoralization, and death anxiety over four years later. The study was a follow up on the findings first reported by the team in 2016.
“Our findings strongly suggest that psilocybin therapy is a promising means of improving the emotional, psychological, and spiritual well-being of patients with life-threatening cancer,” stated Dr. Stephen Ross of the Department of Psychiatry at NYU Langone Health.
Video source: YouTube
Read More Psychedelic Profits Articles Here
Follow Psychedelic Profits on Social Media: Facebook | Twitter | Investor Group
Did you enjoy this article? If so, sign up for our Email Newsletter below to start receiving our weekly recap of the week’s best articles.
Also Read: Bruce Linton and Kevin O’Leary Are Betting Big on This Psychedelics Company
The Rapidly Rising Psychedelics Industry Could Give Cannabis a Run for its Money in 2020
The Most Anticipated U.S. MSO IPO of 2020 is Drawing Near
The Cannabis Sector is Long Overdue for a High-Profile IPO
The Wait is Nearly Over, TCI’s MSO IPO of 2020 is Almost Here
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos